Expanded Pediatric Use of Selumetinib Approved for Inoperable Plexiform Neurofibromas
FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S....
Progress Against Cancer
FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S....
The FDA has approved a delivery system that, once inserted into the bladder, delivers a local dose of the...
The FDA has approved zongertinib for patients with unresectable or metastatic non-squamous non-small cell lung cancer that has HER2...
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline...
The FDA has approved sunvozertinib for certain patients with EGFR-mutated non-small Cell lung cancer. The U.S. Food and Drug...
The FDA has approved linvoseltamab-gcpt for certain patients with heavily pretreated multiple myeloma. The U.S. Food and Drug Administration...
The FDA has approved datopotamab deruxtecan-dlnk for certain patients with non-small cell lung cancer. The U.S. Food and Drug...
The FDA has approved tafasitamab-cxix for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has...
The FDA has approved pembrolizumab for certain patients with previously untreated head and neck cancer. The U.S. Food and...
The FDA has approved mitomycin intravesical solution for certain patients with recurrent non-muscle invasive bladder cancer. The U.S. Food...